Drug Profile
Research programme: Staphylococcus aureus infections - Inhibitex/ZLB
Latest Information Update: 02 Aug 2001
Price :
$50
*
At a glance
- Originator Inhibitex; ZLB Bioplasma
- Developer Inhibitex
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Staphylococcal infections
Most Recent Events
- 02 Aug 2001 Discontinued-Preclinical for Staphylococcal infections in USA (Unknown route)
- 12 Nov 1999 Preclinical development for Staphylococcal infections in USA (Unknown route)